Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
10:37am, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA
5 Stocks in S&P 500 ETF That Gained Last Week
02:10pm, Monday, 20'th Jun 2022 Zacks Investment Research
The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY???s portfolio have risen.
5 Stocks in S&P 500 ETF That Gained Last Week
11:39am, Monday, 20'th Jun 2022
The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY?
Wall Street Breakfast: What Moved Markets
12:08pm, Saturday, 18'th Jun 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.
Seven reasons the beleaguered biotech sector is now a 'buy'
11:33am, Saturday, 18'th Jun 2022 MarketWatch
Investors ought to take advantage of low prices for a long-term view.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
12:31pm, Friday, 17'th Jun 2022 Zacks Investment Research
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
10:50am, Friday, 17'th Jun 2022
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
04:15pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
04:58pm, Wednesday, 15'th Jun 2022
Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per
3 Falling Stocks That Are Still Overpriced
02:15pm, Wednesday, 15'th Jun 2022 The Motley Fool
These are stocks you shouldn't buy on the dip.
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
11:30am, Wednesday, 15'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from clinical studies aimed at assessing remaining unmet needs for people living with spinal mu
3 Falling Stocks That Are Still Overpriced
10:15am, Wednesday, 15'th Jun 2022
These are stocks you shouldn't buy on the dip.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
05:00pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
11:30am, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is celebrating 20 years of caring deeply with the 20th anniversary of the Biogen Foundation and the Biogen Community La
Is Biogen a Bargain or a Bust?
03:15pm, Thursday, 09'th Jun 2022 The Motley Fool
Has the stock become a value trap?
